Alembic Pharmaceuticals Limited has informed the Exchange regarding a revised press release dated November 04, 2025, titled "Revised Press Release for the Q2 FY 26 Results".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals reported consolidated Q2 FY26 revenue of Rs. 1,910 Cr, up 16% year-on-year, with EBITDA rising 26% to Rs. 325 Cr (17% margin) and profit after tax growing 20% to Rs. 185 Cr. The US generics business grew strongly at 21% to Rs. 566 Cr, while ex-US international generics surged 31% to Rs. 392 Cr. India branded business posted a modest 5% growth at Rs. 639 Cr, and the API segment grew 15% to Rs. 261 Cr. The company completed its acquisition of Utility Therapeutics during the quarter, marking a move into branded drugs in the US. Management continues to invest around 10% of revenue in R&D, focusing on injectables, peptides, oral solids, and drug discovery.
Strong double-digit growth in revenue and profits, led by robust international generics performance, is positive for shareholders. The US acquisition and consistent R&D spending suggest a focus on long-term growth, though India business growth remains tepid.